Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea

被引:1
|
作者
Ikegami, T
Ha, L
Arimori, K
Latham, P
Kobayashi, K
Ceryak, S
Matsuzaki, Y
Bouscarel, B
机构
[1] George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA
[2] George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA
[3] George Washington Univ, Med Ctr, Dept Pathol, Washington, DC 20037 USA
[4] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA
[5] Miyazaki Med Coll, Dept Pharm, Miyazaki 8891692, Japan
[6] Saitama Canc Ctr, Ina, Saitama 3360011, Japan
[7] Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3050024, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The therapeutic efficacy of irinotecan (CPT-11), a DNA topoisomerase inhibitor, is often limited by the induction of severe late-onset diarrhea. This prodrug and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have a labile a-hydroxy-lactone ring that undergoes pH-dependent reversible hydrolysis. At physiological pH and higher, equilibrium favors the less toxic carboxylate form, whereas at acidic pH, the more potent lactone form is favored. We have reported previously that the initial uptake rate of CPT-11 and SN-38 by intestinal cells was significantly different between the respective lactone and carboxylate form. Results from the present study in HT-29 cells further demonstrate the correlation between the CPT-11/SN-38 initial uptake rate and the induced toxicity, cell cycle alteration, apoptosis, and colony-forming efficiency. The exposure of HT-29 cells to SN-38 for a limited period of time (<2 h) was sufficient to induce these events. Because the decreased initial uptake of SN-38 carboxylate resulted in a reduced cellular toxicity, we postulated that the CPT-11-induced diarrhea was preventable by influencing the equilibrium toward the carboxylate form and, thus, reducing its intestinal uptake. In the golden Syrian hamster model, p.o. sodium bicarbonate supplementation (5 mg/ml in drinking water) led to alkalization of the intestinal contents. In addition, this alkalization resulted in the reduction of the histopathological damage to the mucosa of the small and large intestine, as well as a 20% reduction of the intestinal SN-38 lactone concentration of animals receiving CPT-11 (20-50 mg/kg X 7 days). Taken together, these results from in vitro and in vivo studies support intestinal alkatization by sodium bicarbonate supplementation as a preventive mechanism against CPT-11-induced diarrhea. In addition, this provides a strong rationale for the usage of this measure as an adjunct to CPT-11 treatment.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [31] Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics
    Yamauchi, T
    Amaya, N
    Yoshio, N
    Yoshida, A
    Tsutani, H
    Ueda, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1999, 69 (03) : 165 - 169
  • [32] Molecular predictor of irinotecan (CPT-11) efficacy.
    Rhodes, KE
    Vallböhmer, D
    Zhang, W
    Yang, DY
    Yun, J
    Press, O
    Gordon, M
    Iqbal, S
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 261S - 261S
  • [33] Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity
    Levi, Mattan
    Ben-Aharon, Irit
    Shalgi, Ruth
    FRONTIERS IN REPRODUCTIVE HEALTH, 2022, 4
  • [34] Investigation of the Possible Protective Effect of N-Acetylcysteine (NAC) against Irinotecan (CPT-11)-Induced Toxicity in Rats
    Gencosman, Sevgi
    Ceylanli, Deniz
    Sehirli, Ahmet Ozer
    Terali, Kerem
    Bolukbasi, Furkan
    Cetinel, Sule
    Sayiner, Serkan
    ANTIOXIDANTS, 2022, 11 (11)
  • [35] A NEW ENKEPHALINASE INHIBITOR AS AN ALTERNATIVE TO LOPERAMIDE IN THE PREVENTION OF DIARRHEA INDUCED BY CPT-11
    GONCALVES, E
    DACOSTA, L
    ABIGERGES, D
    ARMAND, JP
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 2144 - 2146
  • [36] Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion
    Akinobu Kurita
    Shoichi Kado
    Norimasa Kaneda
    Masaharu Onoue
    Shusuke Hashimoto
    Teruo Yokokura
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 349 - 360
  • [37] Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction
    Ong, SYK
    Clarke, SJ
    Bishop, J
    Dodds, HM
    Rivory, LP
    ANTI-CANCER DRUGS, 2001, 12 (07) : 619 - 625
  • [38] Irinotecan (CPT-11) in the elderly: our experience on feasibility and toxicity
    Capello, C
    Milanesi, E
    Evangelisti, L
    Ferraris, C
    Granello, M
    Bellinato, C
    Ferrero, DM
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 226 - 226
  • [39] Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer
    Ashizawa, Tatsuto
    Iwahori, Tohru
    Yokoyama, Takayoshi
    Kihara, Yuu
    Konnno, Osamu
    Jyojima, Yoshimaro
    Akashi, Isao
    Nakamura, Yuuki
    Hama, Kouichirou
    Iwamoto, Hitoshi
    Segawa, Mai
    Takeuchi, Hironori
    Hirano, Toshihiko
    Nagao, Takeshi
    ACTA MEDICA OKAYAMA, 2010, 64 (01) : 19 - 26
  • [40] Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
    Mathijssen, Ron H. J.
    Loos, Walter J.
    Verweij, Jaap
    Sparreboom, Alex
    CURRENT CANCER DRUG TARGETS, 2002, 2 (02) : 103 - 123